Axsome Therapeutics (AXSM) announced that SYMBRAVO is now available by prescription in the United States for the acute treatment of migraine with or without aura in adults. SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that targets multiple brain pathways underlying a migraine attack. SYMBRAVO rapidly provides migraine pain freedom and returns patients to normal functioning at 2 hours versus placebo, with lasting pain freedom sustained from 2 to 24 hours in some patients after a single dose.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Positive Outlook for Axsome Therapeutics Despite Regulatory Setback, Driven by Promising Pipeline and Market Potential
- Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05
- Axsome Therapeutics Shareholders Approve Key Proposals at Meeting
- Axsome’s AXS-14 gets regulatory setback with RTF, says Morgan Stanley
- Axsome Therapeutics’ Growth Prospects Remain Strong Despite FDA Setback on AXS-14